CrossPoint Therapeutics develops next-generation antibody therapies using its proprietary Stealth-Body technology, which features mutations that minimize Fc-effector functions and off-target toxicity. This approach enhances the safety and efficacy of drug candidates, expanding the range of treatable diseases for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody therapies can trigger unintended immune responses and off-target toxicity due to Fc-effector functions, limiting their safety and efficacy in treating various diseases. These side effects can narrow the therapeutic window and restrict the development of antibody-based drugs for sensitive patient populations.
Solution
CrossPoint Therapeutics is developing next-generation antibody therapies with enhanced safety and efficacy using its proprietary Stealth-Body technology. This platform features mutations that minimize Fc-effector functions, thereby reducing off-target toxicity and improving the therapeutic index. By eliminating unwanted immune interactions, Stealth-Body technology expands the range of treatable diseases and allows for the development of safer, more effective antibody drugs. The technology aims to overcome the limitations of conventional antibodies, providing novel treatment options for refractory diseases with high unmet clinical demand. CrossPoint's approach focuses on creating innovative antibody modalities that address challenging indications and improve patient outcomes.
Target Audience
The primary target audience includes patients with refractory diseases and high unmet clinical needs, as well as pharmaceutical companies seeking safer and more effective antibody-based therapeutics.
Features
- Proprietary Stealth-Body technology featuring mutations that reduce Fc-effector functions
- Minimized binding or activity across Fc gamma receptors, surpassing previously described modifications
- Reduced off-target toxicity issues for safer antibody therapies
- Diversified Fc inert antibody platform applicable to various drug modalities